Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

30.47 +0.39 (+1.30%)
Official Closing Price Updated: 7:00 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 45,356,658
Open 30.31
Bid (Size) 30.63 (1)
Ask (Size) 30.69 (10)
Prev. Close 30.08
Today's Range 29.96 - 30.51
52wk Range 28.93 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 5.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
ImmunoGen Stock Nearly Doubled On Thursday: What Happened?
Shares of ImmunoGen Inc. close to doubled this morning after AbbVie Inc. said it will buy the cancer therapies company for $10.1 billion. 
Via Talk Markets

Performance

YTD
-40.56%
-40.56%
1 Month
-0.29%
-0.29%
3 Month
-13.88%
-13.88%
6 Month
-23.35%
-23.35%
1 Year
-39.22%
-39.22%

More News

Read More
Billionaire Favorites: 3 Ultra-High Yield Stocks the Elite Love
Via InvestorPlace
Allergy Treatment Market Know Faster Growing Segments Now: Akorn, Pfizer, Novartis, Mylan N.V
Via SBWire
How To Make $500 A Month With Pfizer Stock
Via Benzinga
How Is The Market Feeling About Pfizer?
Via Benzinga
Is Pfizer Stock a Buy Now?
Via The Motley Fool
Uncovering Dividend Opportunities with NYSE:PFE.
Via Chartmill
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Via SBWire
Loser Stocks: Buy More, Hold Or Sell?
Via Talk Markets
3 Synthetic Biology Stocks Likely to Mint New Millionaires
Via InvestorPlace
Companies That Grow Through Acquisitions: Pros And Cons
Via Talk Markets
J&J, Gilead, BMS: A look at undervalued dividend payers
Via MarketBeat
New Partnership Between Generis And Risetime Provides Easy and Compliant Information Management for Cosmetics Industry
Via PRLog
Exposures Product Safety
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Via Benzinga
3 Top-Rated Value Stocks That Analysts Are Loving Now
Via InvestorPlace
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Why Biodexa Pharmaceuticals Stock (BDRX) Is Skyrocketing
Via Benzinga
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Via Benzinga
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?
Via The Motley Fool
Heart Failure Drugs Market Critical Analysis with Expert Opinion : Johnson & Johnson, Pfizer, Roche
Via SBWire
These Three Biotech Stocks Are Trading At A Discount
Via Talk Markets
Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.
Via Investor's Business Daily
2 Stocks You'll Be Grateful You Bought at These Bargain Prices
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.